Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial

Shenyankangfu Tablet (SYKFT) is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney disease. This trial compared the efficacy and safety of SYKFT, for the control of proteinuria in primary glomerulonephritis patients, against the standard...

Full description

Saved in:
Bibliographic Details
Published in:Journal of integrative medicine 2021-03, Vol.19 (2), p.111-119
Main Authors: Wu, Jie, Duan, Shu-wei, Yang, Hong-tao, Deng, Yue-yi, Li, Wei, He, Ya-ni, Ni, Zhao-hui, Zhan, Yong-li, Lin, Shan, Guo, Zhi-yong, Zhu, Jun, Fang, Jing-ai, Liu, Xu-sheng, Wang, Li-hua, Wang, Rong, Wang, Nian-song, Cheng, Xiao-hong, He, Li-qun, Luo, Ping, Sun, Shi-ren, Sun, Ji-feng, Yin, Ai-ping, Jiang, Geng-ru, Chen, Hong-yu, Liu, Wen-hu, Lin, Hong-li, Liang, Meng, Ma, Lu, Chen, Ming, Song, Li-qun, Chen, Jian, Zhu, Qing, Xing, Chang-ying, Li, Yun, Gao, Ji-ning, Li, Rong-shan, Li, Ying, Zhang, Hao, Lu, Ying, Zhou, Qiao-ling, Fu, Jun-zhou, He, Qiang, Cai, Guang-yan, Chen, Xiang-mei
Format: Article
Language:English
Subjects:
Double blind
Double dummy
Herbal medicine, Chinese
Primary glomerulonephritis
Randomized controlled trial
Shenyankangfu Tablet
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Shenyankangfu Tablet (SYKFT) is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney disease. This trial compared the efficacy and safety of SYKFT, for the control of proteinuria in primary glomerulonephritis patients, against the standard drug, losartan potassium. This was a multicenter, double-blind, randomized, controlled clinical trial. Primary glomerulonephritis patients, aged 18–70 years, with blood pressure ≤ 140/90 mmHg, estimated glomerular filtration rate (eGFR) ≥ 45 mL/min per 1.73 m2, and 24-hour proteinuria level of 0.5–3.0 g, were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups: SYKFT, losartan potassium 50 mg or 100 mg, SYKFT plus losartan potassium 50 mg or 100 mg. The primary outcome was change in the 24-hour proteinuria level, after 48 weeks of treatment. A total of 735 participants were enrolled. The percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78% ± 2.56% (P = 0.006) more than that in the losartan 50 mg group, which was 0.51% ± 2.54% (P = 1.000) less than that in the losartan 100 mg group. Compared with the losartan potassium 50 mg group, the SYKFT plus losartan potassium 50 mg group had a 13.39% ± 2.49% (P 
ISSN:2095-4964
DOI:10.1016/j.joim.2021.01.009